Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Critical Care
Published in: Critical Care 6/2005

Open Access 01-12-2005 | Research

The use of prophylactic fluconazole in immunocompetent high-risk surgical patients: a meta-analysis

Authors: Kwok M Ho, Jeffrey Lipman, Geoffrey J Dobb, Steven AR Webb

Published in: Critical Care | Issue 6/2005

Login to get access

Abstract

Introduction

High-risk surgical patients are at increased risk of fungal infections and candidaemia. Evidence from observational and small randomised controlled studies suggests that prophylactic fluconazole may be effective in reducing fungal infection and mortality. We evaluated the effects of prophylactic fluconazole on the incidence of candidaemia and hospital mortality in immunocompetent high-risk surgical patients.

Methods

Randomised controlled studies involving the use of fluconazole in immunocompetent high-risk surgical patients from the Cochrane Controlled Trial Register (2005, issue 1) and from the EMBASE and MEDLINE databases (1966–30 April 2005), without any language restriction, were included. Two reviewers reviewed the quality of the studies and performed data extraction independently.

Results

Seven randomised controlled studies with a total of 814 immunocompetent high-risk surgical patients were considered. The use of prophylactic fluconazole was associated with a reduction in the proportion of patients with candidaemia (relative risk [RR] = 0.21, 95% confidence interval [CI] = 0.06–0.72, P = 0.01; I2 = 0%) and fungal infections other than lower urinary tract infection (RR = 0.39, 95% CI = 0.24–0.65, P = 0.0003; I2 = 0%), but was associated with only a trend towards a reduction in hospital mortality (RR = 0.82, 95% CI = 0.62–1.08, P = 0.15; I2 = 7%). The proportion of patients requiring systemic amphotericin B as a rescue therapy for systemic fungal infection was lower after prophylactic use of fluconazole (RR = 0.35, 95% CI = 0.17–0.72, P = 0.004; I2 = 0%). The proportion of patients colonised with or infected with fluconazole-resistant fungi was not significantly different between the fluconazole group and the placebo group (RR = 0.66, 95% CI = 0.22–1.96, P = 0.46; I2 = 0%).

Conclusion

The use of prophylactic fluconazole in immunocompetent high-risk surgical patients is associated with a reduced incidence of candidaemia but with only a trend towards a reduction in hospital mortality.
Appendix
Available only for authorised users
Literature
1.
Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB: Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004, 39: 309-317. 10.1086/421946CrossRefPubMed
2.
3.
Dimopoulos G, Piagnerelli M, Berre J, Eddafali B, Salmon I, Vincent JL: Disseminated aspergillosis in intensive care unit patients: an autopsy study. J Chemother 2003, 15: 71-75. 10.1159/000070766CrossRefPubMed
4.
Tufano R: Focus on risk factors for fungal infections in ICU patients. Minerva Anestesiol 2002, 68: 269-272.PubMed
5.
Eggimann P, Garbino J, Pittet D: Management of Candida species infections in critically ill patients. Lancet Infect Dis 2003, 3: 772-785. 10.1016/S1473-3099(03)00831-4CrossRefPubMed
6.
Calandra T, Marchetti O: Clinical trials of antifungal prophylaxis among patients undergoing surgery. Clin Infect Dis 2004, 39 Suppl 4: S185-S192. 10.1086/421955CrossRefPubMed
7.
Diekema DJ, Pfaller MA: Nosocomial candidemia: an ounce of prevention is better than a pound of cure. Infect Control Hosp Epidemiol 2004, 25: 624-626.CrossRefPubMed
8.
Ostrosky-Zeichner L: Prophylaxis or preemptive therapy of invasive candidiasis in the intensive care unit? Crit Care Med 2004, 32: 2552-2553. 10.1097/01.CCM.0000148226.95597.7ECrossRefPubMed
9.
Blumberg HM, Jarvis WR, Soucie JM, Edwards JE, Patterson JE, Pfaller MA, Rangel-Frausto MS, Rinaldi MG, Saiman L, Wiblin RT, Wenzel RP, National Epidemiology of Mycoses Survey (NEMIS) Study Group, et al.: Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey. Clin Infect Dis 2001, 33: 177-186. 10.1086/321811CrossRefPubMed
10.
Rex JH, Sobel JD: Prophylactic antifungal therapy in the intensive care unit. Clin Infect Dis 2001, 32: 1191-1200. 10.1086/319763CrossRefPubMed
11.
Lipsett PA: Clinical trials of antifungal prophylaxis among patients in surgical intensive care units: concepts and considerations. Clin Infect Dis 2004, 39 Suppl 4: S193-S199. 10.1086/421956CrossRefPubMed
12.
Zervos EE, Fink GW, Norman JG, Robson MC, Rosemurgy AS: Fluconazole increases bactericidal activity of neutrophils through non-cytokine-mediated pathway. J Trauma 1996, 41: 465-470.CrossRefPubMed
13.
Jacobs S, Price Evans DA, Tariq M, Al Omar NF: Fluconazole improves survival in septic shock: a randomized double-blind prospective study. Crit Care Med 2003, 31: 1938-1946. 10.1097/01.CCM.0000074724.71242.88CrossRefPubMed
14.
15.
Garbino J, Lew DP, Romand JA, Hugonnet S, Auckenthaler R, Pittet D: Prevention of severe Candida infections in nonneutropenic, high-risk, critically ill patients: a randomized, double-blind, placebo-controlled trial in patients treated by selective digestive decontamination. Intensive Care Med 2002, 28: 1708-1717. 10.1007/s00134-002-1540-yCrossRefPubMed
16.
Pelz RK, Hendrix CW, Swoboda SM, Diener-West M, Merz WG, Hammond J, Lipsett PA: Double-blind placebo-controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients. Ann Surg 2001, 233: 542-548. 10.1097/00000658-200104000-00010PubMedCentralCrossRefPubMed
17.
Eggimann P, Francioli P, Bille J, Schneider R, Wu MM, Chapuis G, Chiolero R, Pannatier A, Schilling J, Geroulanos S, et al.: Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients. Crit Care Med 1999, 27: 1066-1072. 10.1097/00003246-199906000-00019CrossRefPubMed
18.
Sandven P, Qvist H, Skovlund E, Giercksky KE, NORGAS Group, Norwegian Yeast Study Group: Significance of Candida recovered from intraoperative specimens in patients with intra-abdominal perforations. Crit Care Med 2002, 30: 541-547. 10.1097/00003246-200203000-00008CrossRefPubMed
19.
He YM, Lv XS, Ai ZL, Liu ZS, Qian Q, Sun Q, Chen JW, Lei DX, Jiang CQ, Yuan YF: Prevention and therapy of fungal infection in severe acute pancreatitis: a prospective clinical study. World J Gastroenterol 2003, 9: 2619-2621.PubMedCentralPubMed
20.
Ables AZ, Blumer NA, Valainis GT, Godenick MT, Kajdasz DK, Palesch YY: Fluconazole prophylaxis of severe Candida infection in trauma and postsurgical patients: a prospective, double-blind, randomized, placebo-controlled trial. Infect Dis Clin Pract 2000, 9: 169-175.CrossRef
21.
Magill SS, Puthanakit T, Swoboda SM, Carson KA, Salvatori R, Lipsett PA, Hendrix CW: Impact of fluconazole prophylaxis on cortisol levels in critically ill surgical patients. Antimicrob Agents Chemother 2004, 48: 2471-2476. 10.1128/AAC.48.7.2471-2476.2004PubMedCentralCrossRefPubMed
22.
De Waele JJ, Vogelaers D, Blot S, Colardyn F: Fungal infections in patients with severe acute pancreatitis and the use of prophylactic therapy. Clin Infect Dis 2003, 37: 208-213. 10.1086/375603CrossRefPubMed
23.
Sandven P, Giercksky KE, NORGAS Group, Norwegian Yeast Study Group: Yeast colonization in surgical patients with intra-abdominal perforations. Eur J Clin Microbiol Infect Dis 2001, 20: 475-481. 10.1007/s100960100531PubMed
24.
Munshi I, Sleeman D, Parra-Davila E, Erbella J, Silva R, Morejon O, Kirton O, Namias N: Fluconazole prophylaxis in critically ill trauma intensive care unit patients. Crit Care Med 1998,26(Suppl):45A. 10.1097/00003246-199801001-00073CrossRef
25.
Garrelts JC, Schroeder TR, Harrison PB: Impact of fluconazole administration on outcomes in critically ill patients. Ann Pharmacother 2004, 38: 1588-1592. 10.1345/aph.1D441CrossRefPubMed
26.
Swoboda SM, Merz WG, Lipsetta PA: Candidemia: the impact of antifungal prophylaxis in a surgical intensive care unit. Surg Infect (Larchmt) 2003, 4: 345-354. 10.1089/109629603322761409CrossRef
27.
Fisher NC, Cooper MA, Hastings JG, Mutimer DJ: Fungal colonisation and fluconazole therapy in acute liver disease. Liver 1998, 18: 320-325.CrossRefPubMed
28.
Piarroux R, Grenouillet F, Balvay P, Tran V, Blasco G, Millon L, Boillot A: Assessment of preemptive treatment to prevent severe candidiasis in critically ill surgical patients. Crit Care Med 2004, 32: 2443-2449. 10.1097/01.CCM.0000147726.62304.7FCrossRefPubMed
29.
Gotzinger P, Wamser P, Barlan M, Sautner T, Jakesz R, Fugger R: Candida infection of local necrosis in severe acute pancreatitis is associated with increased mortality. Shock 2000, 14: 320-323.CrossRefPubMed
30.
Marr KA: Issues in the design of the fluconazole prophylaxis trials in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 2004, 39 Suppl 4: S170-S175. 10.1086/421952CrossRefPubMed
31.
Winston DJ, Pakrasi A, Busuttil RW: Prophylactic fluconazole in liver transplant recipients. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1999, 131: 729-737.CrossRefPubMed
32.
Silvestri L, van Saene HK, Milanese M, Gregori D: Impact of selective decontamination of the digestive tract on fungal carriage and infection: systematic review of randomized controlled trials. Intensive Care Med 2005, 31: 898-910. 10.1007/s00134-005-2654-9CrossRefPubMed
33.
McNeil MM, Nash SL, Hajjeh RA, Phelan MA, Conn LA, Plikaytis BD, Warnock DW: Trends in mortality due to invasive mycotic diseases in the United States, 1980–1997. Clin Infect Dis 2001, 33: 641-647. 10.1086/322606CrossRefPubMed
34.
Rentz AM, Halpern MT, Bowden R: The impact of candidemia on length of hospital stay, outcome, and overall cost of illness. Clin Infect Dis 1998, 27: 781-788.CrossRefPubMed
35.
Rocco TR, Reinert SE, Simms HH: Effects of fluconazole administration in critically ill patients: analysis of bacterial and fungal resistance. Arch Surg 2000, 135: 160-165. 10.1001/archsurg.135.2.160CrossRefPubMed
36.
Trick WE, Fridkin SK, Edwards JR, Hajjeh RA, Gaynes RP, National Nosocomial Infections Surveillance System Hospitals: Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989–1999. Clin Infect Dis 2002, 35: 627-630. 10.1086/342300CrossRefPubMed
37.
Pfaller MA, Diekema DJ, International Fungal Surveillance Participant Group: Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida. Clin Microbiol Infect 2004, 10 Suppl 1: 11-23. 10.1111/j.1470-9465.2004.t01-1-00844.xCrossRefPubMed
38.
Clancy CJ, Yu VL, Morris AJ, Snydman DR, Nguyen MH: Fluconazole MIC and the fluconazole dose/MIC ratio correlate with therapeutic response among patients with candidemia. Antimicrob Agents Chemother 2005, 49: 3171-3177. 10.1128/AAC.49.8.3171-3177.2005PubMedCentralCrossRefPubMed
Metadata
Title
The use of prophylactic fluconazole in immunocompetent high-risk surgical patients: a meta-analysis
Authors
Kwok M Ho
Jeffrey Lipman
Geoffrey J Dobb
Steven AR Webb
Publication date
01-12-2005
Publisher
BioMed Central
Published in
Critical Care / Issue 6/2005
Electronic ISSN: 1364-8535
DOI
https://doi.org/10.1186/cc3883

Other articles of this Issue 6/2005

Critical Care 6/2005 Go to the issue

Letter

Penetration of the English language in science: the case of a German national interdisciplinary critical care conference

Research

Early hemoperfusion with an immobilized polymyxin B fiber column eliminates humoral mediators and improves pulmonary oxygenation

Commentary

Can we predict septic shock in patients with hospital-acquired pneumonia?

Research

Quantifying bedside-derived imaging of microcirculatory abnormalities in septic patients: a prospective validation study

Commentary

Myocardial infarction complicating critical illness

Web report

icuroom.net – a new critical care addendum